8-K: Scorpius Holdings Faces Asset Sale Amid Defaults

Scorpius Holdings, Inc. received a notice of public disposition, signaling an imminent sale of its pledged assets due to over $26 million in defaults on secured notes.

Summary

• Scorpius Holdings, Inc. received a Notice of Public Disposition under the Uniform Commercial Code from its collateral agent on October 10, 2025.
• The notice indicates multiple defaults under senior secured convertible notes and non-convertible promissory notes.
• The total obligations, including unpaid interest, fees, and expenses, currently exceed $26,048,716.
• The collateral agent will sell all or a portion of the company's and its subsidiaries' pledged assets at a public sale.
• The public sale is scheduled for November 12, 2025, at 10:00 a.m. Eastern Time, to be conducted in-person or remotely.
• Pledged collateral includes all personal property and assets, specifically the company's 94% interest in Scorpius Biomanufacturing, Inc. and 100% interest in Skunkworx Bio, Inc.

Sentiment

Score: 1

Explanation: The company is facing an imminent public sale of substantially all its assets due to multiple defaults on over $26 million in secured notes, indicating severe financial distress and potential liquidation.

Negatives

• Receipt of a Notice of Public Disposition under the Uniform Commercial Code, indicating severe financial distress.
• Multiple defaults on senior secured convertible notes and non-convertible promissory notes.
• Current obligations exceed $26,048,716, including unpaid interest, fees, and expenses.
• Imminent public sale of substantially all company and subsidiary assets, including key equity interests in Scorpius Biomanufacturing, Inc. and Skunkworx Bio, Inc.
• Potential loss of control and ownership over core business assets.

Risks

• Liquidation of substantially all company assets, leading to potential cessation of operations.
• Significant loss of shareholder value, potentially leading to complete equity wipeout.
• Inability to meet financial obligations and potential bankruptcy.
• Loss of control over key subsidiaries, Scorpius Biomanufacturing, Inc. and Skunkworx Bio, Inc.
• Reputational damage and loss of investor confidence.

Future Outlook

The future outlook is extremely negative, with an imminent public sale of substantially all company assets due to multiple defaults. This event strongly suggests a high probability of significant operational disruption, potential cessation of business activities, or a drastic restructuring following the asset disposition.

Industry Context

The biomanufacturing and biotech sectors are often capital-intensive, requiring substantial investment in R&D and infrastructure. This filing indicates severe financial distress for Scorpius Holdings, suggesting a failure to secure adequate funding, manage debt effectively, or achieve operational profitability. Such an event could raise concerns about the financial viability of smaller, less established companies within the broader industry, particularly those reliant on external financing.

Comparison to Industry Standards

• This event represents a severe deviation from industry standards for financially healthy companies, indicating significant distress and a failure to meet debt obligations.
• Companies typically aim to avoid defaults and asset liquidations, which are indicators of profound financial mismanagement or insurmountable operational challenges.
• The filing does not provide specific comparable companies, projects, or results for a direct benchmark, but the situation is indicative of a company in a critical state, far below typical industry performance benchmarks.

Stakeholder Impact

• Shareholders: Face a high probability of significant or complete loss of investment due to the liquidation of company assets.
• Employees: Likely to experience job insecurity, potential layoffs, and disruption to employment.
• Creditors (unsecured): Unlikely to recover funds given the secured nature of the defaulted notes and the asset sale.
• Customers and Suppliers: May face disruption of services, contracts, and business relationships due to the company's financial distress and potential operational changes.

Next Steps

• Public sale of collateral pledged by the company and its subsidiaries on November 12, 2025, at 10:00 a.m. (Eastern Time).

Key Dates

Recommendation

The company is in severe financial distress, evidenced by multiple defaults on over $26 million in secured notes and the imminent public sale of substantially all its assets. This event signals a high probability of significant shareholder value destruction, potential bankruptcy, or delisting, making a strong sell recommendation appropriate to mitigate further losses.

Keywords

Scorpius Holdings, default, secured notes, asset sale, collateral agent, public disposition, financial distress, biomanufacturing, Skunkworx Bio, UCC